Free Trial
Derek Archila

Derek Archila Analyst Performance

Managing Director, Biotechnology Equity Research at Wells Fargo & Company

Derek Archila is a stock analyst at Wells Fargo & Company in the medical sector, covering 52 publicly traded companies. Over the past year, Derek Archila has issued 27 stock ratings, including buy and hold recommendations. While full access to Derek Archila's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Derek Archila's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
259 Last 8 Years
Buy Recommendations
61.87% 159 Buy Ratings
Companies Covered
52 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy0.4%1 ratings
Buy61.5%158 ratings
Hold38.1%98 ratings
Sell0.0%0 ratings

Out of 257 total stock ratings issued by Derek Archila at Wells Fargo & Company, the majority (61.5%) have been Buy recommendations, followed by 38.1% Hold and 0.4% Strong Buy.

Exchange Coverage

ExchangePercentageCount
NASDAQ
92.3% of companies on NASDAQ
48 companies
NYSE
7.7% of companies on NYSE
4 companies

Derek Archila, an analyst at Wells Fargo & Company, currently covers 52 companies listed on NASDAQ and NYSE, with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Medical
52 companies
100.0%

Derek Archila of Wells Fargo & Company specializes in stock coverage within the Medical sector.

Coverage Industries

IndustryPercentage
MED - BIOMED/GENE
26 companies
50.0%
PHARMACEUTICAL PREPARATIONS
16 companies
30.8%
MED - DRUGS
4 companies
7.7%
BIOTECHNOLOGY
3 companies
5.8%
BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC
1 company
1.9%
MED PRODUCTS
1 company
1.9%
MED - GENERIC DRG
1 company
1.9%

About Derek Archila

Senior Equity Research Analyst specializing in small- and mid-cap biotechnology companies, with a primary focus on immunology & inflammation (I&I), targeted oncology, and rare diseases. I am a key contributor to the #4 ranked Wells Fargo SMID-cap biotech franchise, and was individually recognized as a “Runner-Up” in the Institutional Investor (Extel) poll for Biotechnology Small & Mid-Cap Equity Research in both 2023 and 2024, ranking among the top 5 analysts in 2024.
Follow on LinkedIn

Derek Archila's Ratings History at Wells Fargo & Company

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
aTyr Pharma, Inc. stock logo
ATYR
aTyr Pharma
9/15/2025Reiterated Rating$1.05Equal Weight
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
8/20/2025Initiated Coverage$66.81$123.00Overweight
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
8/20/2025Lower Price Target$21.24$38.00Overweight
Sutro Biopharma, Inc. stock logo
STRO
Sutro Biopharma
8/12/2025Lower Price Target$0.77$3.00Equal Weight
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
8/8/2025Reiterated Rating$190.35$295.00Overweight
Viridian Therapeutics, Inc. stock logo
VRDN
Viridian Therapeutics
8/7/2025Lower Price Target$16.71$26.00Equal Weight
Arvinas, Inc. stock logo
ARVN
Arvinas
8/7/2025Lower Price Target$6.14$16.00Overweight
Zentalis Pharmaceuticals, Inc. stock logo
ZNTL
Zentalis Pharmaceuticals
8/7/2025Lower Price Target$1.43$5.00Equal Weight
Incyte Corporation stock logo
INCY
Incyte
8/6/2025Upgrade$77.72$89.00Overweight
argenex SE stock logo
ARGX
argenex
7/31/2025Boost Price Target$670.33$756.00Overweight
Incyte Corporation stock logo
INCY
Incyte
7/30/2025Boost Price Target$77.88$67.00Equal Weight
Alumis Inc. stock logo
ALMS
Alumis
7/25/2025Initiated Coverage$4.05$17.00Overweight
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
7/10/2025Boost Price Target$89.53$129.00Overweight
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
6/26/2025Lower Price Target$44.98$53.00Overweight
aTyr Pharma, Inc. stock logo
ATYR
aTyr Pharma
6/20/2025Boost Price Target$5.17$25.00Overweight
Blueprint Medicines Corporation stock logo
BPMC
Blueprint Medicines
6/17/2025Downgrade$128.16$129.00Hold
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
6/2/2025Boost Price Target$19.21$29.00Equal Weight
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
5/8/2025Lower Price Target$17.90$26.00Equal Weight
Arvinas, Inc. stock logo
ARVN
Arvinas
5/2/2025Lower Price Target$7.78$19.00Overweight
Incyte Corporation stock logo
INCY
Incyte
4/30/2025Boost Price Target$61.16$59.00Equal Weight
Nurix Therapeutics, Inc. stock logo
NRIX
Nurix Therapeutics
4/9/2025Lower Price Target$9.86$25.00Overweight
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
4/7/2025Boost Price Target$54.94$91.00Overweight
Arvinas, Inc. stock logo
ARVN
Arvinas
3/12/2025Set Price Target$8.51$26.00Overweight
argenex SE stock logo
ARGX
argenex
2/28/2025Boost Price Target$619.04$741.00Overweight
Exelixis, Inc. stock logo
EXEL
Exelixis
2/24/2025Downgrade$36.85$36.00Equal Weight
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
2/13/2025Boost Price Target$19.29$51.00Overweight
Zentalis Pharmaceuticals, Inc. stock logo
ZNTL
Zentalis Pharmaceuticals
1/30/2025Lower Price Target$1.66$6.00Equal Weight